source
- Scaling delivery is key for CAR T therapies to succeed in autoimmune diseasesBiopharma companies are exploring CAR T cell therapies as a potential cure for autoimmune disorders, a market that could be twice the size of oncology. While current treatments manage symptoms, the…
- SK Biopharma signs $795 million licensing deal with Biohaven for epilepsy therapy opakalimSK Biopharma has entered a licensing agreement with Biohaven Pharmaceuticals to acquire worldwide rights to the Kv7 ion channel activator opakalim (BHV-7000) for epilepsy. The deal provides an upf…